Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
- Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
- Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.
Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.
The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.
Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”
Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.
For further information, please visit: www.fair-med.com/newsroom
Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690
Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.
Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.
Images

Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
HEIDELBERG sees clear increase in profitability in third quarter of financial year 2024/202512.2.2025 09:03:39 CET | Press release
Q3 sales at previous year’s level and adjusted EBITDA margin improves significantly to 9.2 percent Incoming orders up 8.3 percent for Q3 and 7.7 percent after nine months compared with previous year High order backlog points to strong final quarter Full-year forecast confirmed, adjusted EBITDA margin to rise to up to around 8 percent in FY 2025/2026 Packaging remains a growth driver Growth strategy promises sales potential of over € 300 million in medium term
German WPC specialist Naturinform engages experienced export director and manager11.2.2025 10:13:49 CET | Press release
Redwitz a.d. Rodach German WPC (Wood-Polymer-Composite) specialist Naturinform increases its international business and further expands its market presence. By engaging Edward Robinson as the Director of International Business Development, the enterprise relies on an experienced industry specialist in order to strategically advance its export business even more. A native of England, Robinson boasts with nearly 20 years of experience in the European composites industry, recently holding the same leading position at UPM-Profi.
Hollywood Meets the Art of Design and Engineering: Orlando Bloom Presents Porsche Design Timepieces and Eyewear.6.2.2025 09:34:28 CET | Press release
Stuttgart, Germany. Porsche Design is proud to announce that Orlando Bloom will be the new Brand Ambassador for the brand’s Timepiece and Eyewear collections. Known for his celebrated roles in numerous films and regarded as one of Hollywood’s most stylish leading men, Orlando Bloom is also a long-time Porsche enthusiast. His appreciation for the exceptional design, technical innovation and functionality that define Porsche Design makes this an ideal partnership. In the new image campaign for Porsche Design, Orlando Bloom wears the iconic Chronograph 1 timepiece, along with seven selected models of the brand’s innovative sunglasses and prescription eyewear.
Nexaro presenterer den nye Nexaro NR 1700: Betydelig økning i effektivitet og utvidede bruksmuligheter for mer komplekse krav5.2.2025 16:00:00 CET | Press release
Wuppertal, februar 2025 – Etter verdens første kompakte robotstøvsuger, Nexaro NR 1500, som ble sertifisert for rengjøring av kommersielle bygninger, utvider den Wuppertal-baserte teknologioppstarten Nexaro nå sitt produktspekter med en annen innovativ robotstøvsuger, Nexaro NR 1700. Den nye modellen er spesielt utviklet for å møte kravene til rengjøring av større og mer komplekse rom i et profesjonelt miljø enda mer effektivt. Utviklingen av den nye intelligente vakuumroboten er basert på Nexaros nære samarbeid med ledende nasjonale og internasjonale rengjøringsselskaper. Nexaro tar neste skritt for å sikre den fremtidige levedyktigheten til markedet for rengjøring av kommersielle bygninger.
CO.DON GmbH partners in EU-Funded Project to Advance 3D Bioprinting for Tissue Regeneration5.2.2025 15:00:00 CET | Press release
Teltow, 05. February 2025 – The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom